TMCnet News
NetNoggin® announces the release of NetNog: #genesis® Cystic Fibrosis researchFREDERICK, Md., Oct. 19, 2018 /PRNewswire/ -- NetNoggin®, a premier market research agency that specializes in pharmaceutical marketing, has announced the release of its newest research, NetNog: #genesis® Cystic Fibrosis. https://netnoggin.net/products "We started with a rare condition because we truly care about the patient's story, and this story needs to be heard," said Megan Newcomer, Marketing Director at NetNoggin®. "We have the ability, with NetNog: #genesis®, to look at the disease market as a whole and really analyze how we can improve it, and ideally, improve the lives of patients and caregivers who struggle with this condition." NetNog: #genesis® Cystic Fibrosis offers pharmaceutical companies an unprecedented advantage by starting their research with:
NetNog: #genesis® is foundational research grounded in netnography and supported with secondary research to provide context to the disease-state. Cystic fibrosis is the first disease-focused research published in the NetNog: #genesis® pipeline, however, Alzheimer's disease (including MCI), along with other research will be coming to market soon. Visit https://netnoggin.net/products to learn more about NetNog: #genesis® Cystic Fibrosis. About NetNoggin® NetNoggin® Media Relations
View original content to download multimedia:http://www.prnewswire.com/news-releases/netnoggin-announces-the-release-of-netnog-genesis-cystic-fibrosis-research-300734067.html SOURCE NetNoggin |